Mattias Lorentzon

Professor/ Chief Physician

Department of Internal Medicine and Clinical
Visiting address
Postal address
Su sahlgrenska
41345 Göteborg

About Mattias Lorentzon

About Mattias Lorentzon

Mattias Lorentzon is a professor in geriatric medicine at the Institute of Medicine, Gothenburg University, and Chief physician at the Osteoporosis Clinic at the Sahlgrenska University Hospital, Mölndal. He is also the director of the regional Fracture Liaison Service Program in Västra Götaland and the founder of the Sahlgrenska University Hospital Fracture Liaison Service in Gothenburg. He currently leads the Clinical Osteoporosis Research Group at the Sahlgrenska Osteoporosis Centre at the University of Gothenburg. In addition, he is the program leader for the Bone Health and Fractures Research Program at the Australian Catholic University in Melbourne, Australia.

As president of the Swedish Osteoporosis Society (2011-2015) and an expert reviewer in outlining diagnosis and treatment guidelines for the National Board of Health and Welfare (Socialstyrelsen), he has prominently contributed to the development of osteoporosis evaluation and treatment guidelines in Sweden. He is frequently consulted as a reviewer for many scientific journals including the NEJM, JBMR, JCEM, Osteoporosis International, and Annals of Internal Medicine. In addition, he serves as a member of the editorial board of Osteoporosis International.

Research interests and publications

His main research interests include osteoporosis and fracture epidemiology, fracture risk prediction, novel evaluation of bone strength, as well as determining the role of the gut microbiota on bone health. He has led and completed several RCTs investigating the effect of probiotic supplements. He is also the principal investigator of the large, prospective SUPERB cohort study, designed to identify novel factors for osteoporosis and fracture prediction in older women. As principal investigator in Sweden, he has also made a substantial contribution to the development of the currently most effective and recently registered osteoporosis drug romosozumab. He currently leads several intervention studies in Gothenburg and in Melbourne investigating the effects of both 1st and 2nd generation probiotics on bone health. He is also an active member of the FRAXresearch team, an internationally leading osteoporosis epidemiology group developing fracture prediction models.

He has contributed significantly to osteoporosis research, with over 260 peer-reviewed publications, including seminal publications in NEJM, JAMA, Nature, Nature genetics, and the Lancet, with over 30.000 citations (Aug2022).


· Google scholar citations (Aug 2022): 30.000 citations (>17.500 since 2017); h-index 76.

· 260 peer-reviewed original publications (28 as first author and 47 as senior author).

· Number of articles with high impact factor = 36, including articles in the New England Journal of Medicine [IF 176], JAMA [IF 157.3, x2], Nature Genetics [IF 38, x6], Lancet [IF 202.7], Lancet Diabetes and Endocrinology [IF 44.9, x2], Nature Communications [IF 14.9, x6], J Clinical Investigation [IF 15], JAMA Network Open (IF 13.4), American J Human Genetics [IF 11], Molecular Psychiatry [IF 16], J Internal Medicine [IF 13.1, x9].

· 50 publications in the Journal of Bone and Mineral Research, the most prestigious journal in the field of metabolic bone diseases.

· Co-author of 24 publications from the FRAX team regarding the development and clinical utility of FRAX, the leading fracture prediction tool used in over 100 guidelines worldwide.

· Author on several publications with a large impact on current clinical osteoporosis guidelines, with publications covering e.g. the role of osteoporosis medication in patients with prednisolone (JAMA 2017), the usefulness of fracture liaison services in secondary prevention of fractures (JBMR 2020), the superiority of romosozumab over standard therapy (alendronate), making sequential osteoporosis treatment (anabolic followed by antiresorptive) the new gold standard (NEJM 2017).

Selected publications

· Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey E, Liu E, Kanis JA, Litsne H, Lorentzon M. JAMA Netw Open. 2022 Jun 1;5(6):e2215396. doi: 10.1001/jamanetworkopen. 2022.15396.

· Association Between Recurrent Fracture Risk and Implementation of Fracture Liaison Services in four Swedish hospitals A Cohort Study. Axelsson KF, Johansson H, Lundh D, Möller M, Lorentzon M. J Bone Miner Res. 2020 Feb 25. doi: 10.1002/jbmr.3990

· Grade 1 Vertebral Fractures Identified by Densitometric Lateral Spine Imaging Predict Incident Major Osteoporotic Fracture Independently of Clinical Risk Factors and Bone Mineral Density in Older Women. Johansson L, Sundh D, Magnusson P, Rukmangatharajan K, Mellström D, Nilsson AG, Lorentzon M. J Bone Miner Res. 2020 Jun 15. doi: 10.1002/jbmr.4108

· Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. N Engl J Med. 2017 Sep 11. doi: 10.1056/NEJMoa1708322.

· Lactobacillus reuteri reduces bone loss in older women with low bone mineral density - a randomized, placebo-controlled, double-blind, clinical trial. Nilsson AG, Sundh D, Bäckhed F, Lorentzon M. J Intern Med. 2018 Jun 21. doi: 10.1111/joim.12805.

· Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone. Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M. JAMA. 2017 Jul 11;318(2):146-155. doi: 10.1001/jama.2017.8040.

· Increased cortical porosity in women with hip fracture. Sundh D, Nilsson AG, Nilsson M, Johansson L, Mellström D, Lorentzon M. J Intern Med. 2017 May;281(5):496-506